PF-Atlas › Clinical Trials › NCT00125346

Tobramycin Inhalation Powder in Cystic Fibrosis Subjects

Tobramycin Inhalation Powder · Phase 3

Registry ID
NCT00125346
Phase
Phase 3
Status
Terminated
Drug / intervention
Tobramycin Inhalation Powder
Sponsor
Novartis
Start
2005-09

About this trial

Tobramycin Inhalation Powder is evaluated in NCT00125346, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Novartis. Current status: Terminated.

View NCT00125346 on ClinicalTrials.gov →

Explore related

All Tobramycin Inhalation Powder trialsAll IPF trials

Related trials

Tobramycin inhalation powder — NCT00982930Tobramycin Inhalation Powder — NCT01844778
Medical disclaimer. This page summarizes public trial data for NCT00125346 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.